LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Search

Charles River Laboratories International Inc

Fermé

SecteurSoins de santé

168.66 -1.6

Résumé

Variation du prix de l'action

24h

Actuel

Min

167.72

Max

174.52

Chiffres clés

By Trading Economics

Revenu

2.9M

56M

Ventes

-27M

1B

P/E

Moyenne du Secteur

592.3

105.69

BPA

2.43

Marge bénéficiaire

5.529

Employés

18,700

EBITDA

-23M

198M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+11.95% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-487M

8.3B

Ouverture précédente

170.26

Clôture précédente

168.66

Sentiment de l'Actualité

By Acuity

21%

79%

49 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Charles River Laboratories International Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 nov. 2025, 21:34 UTC

Résultats

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 nov. 2025, 23:45 UTC

Market Talk

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 nov. 2025, 23:42 UTC

Acquisitions, Fusions, Rachats

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 nov. 2025, 23:41 UTC

Market Talk

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 nov. 2025, 23:24 UTC

Résultats

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 nov. 2025, 23:24 UTC

Résultats

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 nov. 2025, 23:23 UTC

Résultats

JBS NV 3Q EPS 52c >JBS

13 nov. 2025, 23:23 UTC

Résultats

JBS NV 3Q Sales $22.6B >JBS

13 nov. 2025, 23:04 UTC

Market Talk

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 nov. 2025, 22:02 UTC

Résultats

Nu Holdings 3Q Net $783M >NU

13 nov. 2025, 22:01 UTC

Résultats

Nu Holdings 3Q Rev $4.2B >NU

13 nov. 2025, 21:51 UTC

Acquisitions, Fusions, Rachats

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 nov. 2025, 21:50 UTC

Résultats

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 nov. 2025, 21:45 UTC

Acquisitions, Fusions, Rachats

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 nov. 2025, 21:41 UTC

Acquisitions, Fusions, Rachats

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 nov. 2025, 21:36 UTC

Acquisitions, Fusions, Rachats

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 nov. 2025, 21:36 UTC

Acquisitions, Fusions, Rachats

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 nov. 2025, 21:36 UTC

Acquisitions, Fusions, Rachats

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 nov. 2025, 21:36 UTC

Acquisitions, Fusions, Rachats

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 nov. 2025, 21:36 UTC

Acquisitions, Fusions, Rachats

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 nov. 2025, 21:33 UTC

Market Talk

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 nov. 2025, 21:33 UTC

Résultats

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 nov. 2025, 21:31 UTC

Résultats

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 nov. 2025, 21:25 UTC

Résultats

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 nov. 2025, 21:25 UTC

Résultats

Figure Tech Solutions 3Q EPS 34c >FIGR

13 nov. 2025, 21:23 UTC

Résultats

Intchains Group 3Q Rev $1.3M >ICG

13 nov. 2025, 21:03 UTC

Résultats

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 nov. 2025, 21:02 UTC

Résultats

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 nov. 2025, 21:01 UTC

Résultats

Applied Materials 4Q Rev $6.8B >AMAT

13 nov. 2025, 21:01 UTC

Résultats

Applied Materials 4Q Gross Margin 48.0% >AMAT

Comparaison

Variation de prix

Charles River Laboratories International Inc prévision

Objectif de Prix

By TipRanks

11.95% hausse

Prévisions sur 12 Mois

Moyen 192 USD  11.95%

Haut 225 USD

Bas 165 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

12 ratings

6

Achat

6

Maintien

0

Vente

Score Technique

By Trading Central

117.16 / 144.77Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

49 / 374Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat